TGM2 and breast carcinoma: We have recently demonstrated that detection of any of these EMT-related transcription factors (EMT-TFs) or TGM2 in the peripheral blood of breast cancer patients can serve as a surrogate for circulating tumor cells (CTC) in breast cancer patients [16].